KZIA
Kazia Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.66 / 10
Netural
Analyst coverage is limited to a single Strong‑Buy recommendation, yet past performance is poor (0% win rate, –23.6% return) and the stock has fallen 11.7%. Fund‑flow is positive (score 7.3), with large‑cap investors net inflowing while smaller tiers show outflows, creating mixed sentiment.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate0.0%
Is money flowing into or out of KZIA?
- KZIA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.66/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
